Printer Friendly

Teleflex gains patent for suture and CE mark for catheter device.

Shortly after agreeing to sell its orthopedics business, other divisions of Teleflex continue to make gains. The company's Semprus BioSciences subsidiary has been issued CE certification from its notified body, the DEKRA Certification Group of the Netherlands, to market the company's Nylus peripherally inserted central catheter (PICC) with Semprus Sustain technology in the European Union.

The Nylus PICC uses a long-lasting polymer designed to reduce the attachment of platelets and blood proteins at the surface of the medical device. According to Teleflex, the device can reduce platelet adhesion and thrombus accumulation through both in-vitro and animal testing.

"This clearance enables us to further advance a new standard of care in PICC catheters,"said David L. Lucchino, co-founder of Semprus BioSciences and vice president of strategic and business development at Teleflex. "Our technology, with its ability to work in blood products and long-term duration, holds great potential to reduce infection and thrombus-related complications for patients--while substantially decreasing associated healthcare costs."

Based in Limerick, Pa., Teleflex produces products for the critical care market. Its subsidiary, Semprus BioSciences, is headquartered in Cambridge, Mass., and was acquired by Teleflex in May.

Meanwhile, Teleflex's maker of custom sutures and performance fibers--Teleflex Medical OEM--has received a patent from the U.S. Patent and Trademark Office for a high-strength suture. The suture combines a proprietary coreless braid design with fibers of ultrahigh molecular weight polyethylene (UHMWPE), and the technology also is applicable to UHMWPE material co-braided with colored fibers to create greater visibility and contrast during surgical procedures.

"Teleflex Medical OEM continues to pursue innovations in performance fibers and specialty sutures," said Richard Gallagher, global director of research, development and engineering for Teleflex Medical OEM.


The suture has been marketed under the name Force Fiber since 2004. Its physical properties and handling characteristics have made it a popular choice for arthroscopic repairs, the company claims. The suture is said to be flexible, nonabrasive, and silken in texture that is gentle on both biologic tissue and surgical gloves. When tied, the coreless braid is designed to flatten up in itself to provide a low knot profile that resists slippage and offers knot security.

The Force Fiber portfolio includes a range of U.S. Pharmacopeia-defined sizes, patterns such as cross and stripe, and a selection of solids and multi-colored sutures, including blue, white, green, white/blue, green/white, white/black and white/green.

Teleflex Medical OEM has private label agreements with orthopedic medical device manufacturers to market Force Fiber suture for orthopedic applications. In addition, Force Fiber suture is used as a component in numerous orthopedic medical devices.

Teleflex Medical OEM is a subsidiary of Teleflex Inc., and is headquartered in Kenosha, Wis. The performance fibers business is located in Mansfield, Mass.
COPYRIGHT 2012 Rodman Publishing
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:New Technology Update
Publication:Medical Product Outsourcing
Date:Sep 1, 2012
Previous Article:FDA OKs new drug delivery system from Codman & Shurtleff.
Next Article:Vascular Solutions releases flexible tip microcatheter.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters